🏷

Classifications

Harrison's Chapter

ICD-O Morphology

◆

Subtypes

3

Squamous Cell Carcinoma

The most common histologic type, accounting for approximately 70-80% of cases. Arises from the squamous epithelium of the ectocervix, typically at the transformation zone where squamous and glandular epithelia meet.

Adenocarcinoma

Accounts for 20-25% of cervical cancers. Arises from the glandular epithelium of the endocervical canal. Often HPV-18 associated. May be more difficult to detect by cytology screening.

Adenosquamous Carcinoma

Mixed tumors with both squamous and glandular differentiation. Generally associated with worse prognosis than pure squamous cell carcinoma.

⚙

Pathophysiology

8

E6 Oncoprotein-Mediated p53 Degradation

The HPV E6 oncoprotein binds to the cellular E3 ubiquitin ligase E6AP and targets p53 for proteasomal degradation. Loss of p53 function eliminates DNA damage checkpoints, allows cells with genomic instability to survive, and prevents apoptosis of infected cells.

epithelial cell of cervix link

proteasome-mediated ubiquitin-dependent protein catabolic process link ↑ INCREASED apoptotic process link ↓ DECREASED

uterine cervix link

Downstream

Loss of DNA Damage Response p53 degradation removes critical cell cycle checkpoints

Genomic Instability Cells with damaged DNA continue to proliferate

Show evidence (1 reference)

PMID:2175676 SUPPORT In Vitro

"that bind p53 stimulate the degradation of p53."

Classic mechanistic evidence shows high-risk HPV E6 promotes p53 degradation, supporting p53 checkpoint loss as a central cervical cancer mechanism.

Loss of DNA Damage Response

E6-mediated degradation of p53 weakens DNA-damage checkpoint and apoptosis responses, allowing damaged cervical epithelial cells to survive instead of undergoing growth arrest or programmed cell death.

DNA damage response link ↓ DECREASED cell cycle checkpoint signaling link ↓ DECREASED

Downstream

Genomic Instability Cells with unrepaired damage persist and acquire additional alterations

Show evidence (1 reference)

PMID:2175676 SUPPORT In Vitro

"p53 is ATP dependent and involves the ubiquitin-dependent protease system."

p53 degradation provides direct mechanistic support for impaired p53-mediated DNA damage response and checkpoint control.

Genomic Instability

HPV integration and impaired checkpoint control are associated with structural genomic aberrations, supporting the accumulation of alterations that help drive malignant progression.

DNA damage response link ⚠ ABNORMAL

Downstream

Cervical Intraepithelial Neoplasia Progression Genomic alterations contribute to progression from preinvasive lesions

Show evidence (1 reference)

PMID:28112728 SUPPORT Human Clinical

"aberrations and increased target-gene expression."

Human cervical tumor genomic data link HPV integration with structural aberrations, supporting genomic instability in HPV-driven carcinogenesis.

E7 Oncoprotein-Mediated pRB Inactivation

The HPV E7 oncoprotein binds to and inactivates the retinoblastoma protein (pRB), releasing E2F transcription factors to drive uncontrolled cell cycle progression. E7 also targets pRB family members p107 and p130, and destabilizes pRB through proteasomal degradation.

G1/S transition of mitotic cell cycle link ⚠ ABNORMAL cell cycle checkpoint signaling link ↓ DECREASED

Downstream

Uncontrolled Cell Proliferation E2F release drives S-phase entry independent of growth signals

Show evidence (1 reference)

PMID:2537532 SUPPORT In Vitro

"form similar complexes with p105-RB. Human papilloma virus-16 is found"

Classic biochemical evidence shows HPV16 E7 binds the retinoblastoma gene product, supporting pRB-pathway inactivation.

Uncontrolled Cell Proliferation

E7 binding to pRB disrupts retinoblastoma-mediated cell-cycle restraint, enabling inappropriate S-phase entry and proliferation of HPV-transformed cervical epithelial cells.

cell population proliferation link ↑ INCREASED G1/S transition of mitotic cell cycle link ↑ INCREASED

Downstream

Cervical Intraepithelial Neoplasia Progression Persistent proliferative signaling contributes to preinvasive lesion progression

Show evidence (1 reference)

PMID:2537532 SUPPORT In Vitro

"implicate RB binding as a possible step in human papilloma"

RB binding by HPV16 E7 supports transformation through loss of RB-mediated cell-cycle control.

HPV Genome Integration

Integration of HPV DNA into the host genome disrupts the viral E2 gene, which normally represses E6/E7 expression. This results in constitutive overexpression of E6 and E7 oncoproteins, a critical step in malignant progression from CIN3 to invasive carcinoma.

viral genome integration into host DNA link

Downstream

Constitutive E6/E7 Expression Loss of E2 repression leads to unchecked oncoprotein production

Show evidence (1 reference)

PMID:28112728 SUPPORT Human Clinical

"aberrations and increased target-gene expression."

TCGA confirmed near-universal HPV integration in HPV18-positive cervical cancers and frequent integration in HPV16-positive cancers, linked to host structural alterations and target-gene upregulation.

Constitutive E6/E7 Expression

HPV integration-associated loss of viral regulatory control sustains expression of the E6 and E7 viral oncoproteins, feeding the p53 and pRB disruption arms of cervical carcinogenesis.

Downstream

E6 Oncoprotein-Mediated p53 Degradation Sustained E6 expression drives p53 degradation

E7 Oncoprotein-Mediated pRB Inactivation Sustained E7 expression drives pRB inactivation

Show evidence (2 references)

PMID:28112728 SUPPORT Human Clinical

"aberrations and increased target-gene expression."

TCGA cervical tumor data support integration-associated increased target gene expression, consistent with persistent oncogene expression.

PMID:2175676 SUPPORT In Vitro

"one of two viral products expressed in HPV-associated cancers. E6 is an"

This establishes E6 as an expressed viral oncoprotein in HPV-associated cancers.

Cervical Intraepithelial Neoplasia Progression

HPV infection induces a spectrum of preinvasive lesions graded as CIN1, CIN2, and CIN3 (carcinoma in situ). Low-grade lesions (CIN1) often regress, while high-grade lesions (CIN2/3) have significant risk of progression to invasive carcinoma over 10-20 years if untreated.

cell population proliferation link ↑ INCREASED

Show evidence (1 reference)

PMID:12953088 SUPPORT Human Clinical

"Precursor lesions of the cervix persist longer and progress more"

A longitudinal HPV/CIN cohort supports oncogenic HPV-associated persistence and faster progression of cervical precursor lesions.

✶

Histopathology

1

Squamous Cell Carcinoma VERY_FREQUENT

Squamous cell carcinoma is the most common malignant cervical tumor.

Show evidence (1 reference)

PMID:14690308 SUPPORT

"Squamous cell carcinoma is the most common malignant cervical tumor"

Abstract reports squamous cell carcinoma as the most common malignant cervical tumor.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

4

Genitourinary 2

Abnormal Vaginal Bleeding FREQUENT Metrorrhagia (HP:0100608)

Show evidence (1 reference)

PMID:29794500 SUPPORT Human Clinical

"Common symptoms were abnormal vaginal bleeding, low abdominal pain, and malodorous vaginal discharge reported among 75.8%, 66.4%, and 39.6% of cases, respectively."

Retrospective review of 149 cervical cancer patients in Botswana identifies abnormal vaginal bleeding as the most common presenting symptom (75.8%), supporting its classification as a frequent diagnostic phenotype.

Hematuria FREQUENT Hematuria (HP:0000790)

Show evidence (1 reference)

PMID:23244084 SUPPORT Human Clinical

"A total of 130 were patients included, 54 of which (41.5%) had hematuria."

Prospective study of 130 newly diagnosed cervical cancer patients quantifies hematuria prevalence (41.5%), with hematuria shown to be a sensitive screening test for urinary bladder mucosal infiltration in advanced cervical cancer, supporting classification as a frequent phenotype.

Constitutional 1

Pelvic Pain FREQUENT Abdominal pain (HP:0002027)

Show evidence (1 reference)

PMID:29794500 SUPPORT Human Clinical

"Common symptoms were abnormal vaginal bleeding, low abdominal pain, and malodorous vaginal discharge reported among 75.8%, 66.4%, and 39.6% of cases, respectively."

Low abdominal pain was reported in 66.4% of cervical cancer patients in this Botswana cohort, with the same study identifying low abdominal pain as a significant predictor of locally advanced disease at presentation.

Other 1

Vaginal Discharge FREQUENT

No suitable specific HP term for vaginal discharge was identified in the current ontology build; phenotype captured clinically as abnormal genital tract secretion.

Show evidence (1 reference)

PMID:29794500 SUPPORT Human Clinical

"Common symptoms were abnormal vaginal bleeding, low abdominal pain, and malodorous vaginal discharge reported among 75.8%, 66.4%, and 39.6% of cases, respectively."

Same Botswana retrospective review reports malodorous vaginal discharge in 39.6% of cervical cancer cases, supporting its classification as a frequent presenting symptom.

🧬

Genetic Associations

2

TP53 (Inactivated by E6 Oncoprotein)

PIK3CA (Somatic Mutations)

💊

Treatments

5

HPV Vaccination

Action: vaccination MAXO:0001017

Prophylactic vaccination against HPV-16, 18, and other high-risk types prevents infection and subsequent development of cervical cancer and precancerous lesions. Most effective when administered before sexual debut.

Cone Biopsy/LEEP

Action: surgical procedure MAXO:0000004

Loop electrosurgical excision procedure (LEEP) or cold knife cone biopsy for treatment of high-grade cervical intraepithelial neoplasia (CIN2/3). Allows fertility preservation while treating preinvasive disease.

Radical Hysterectomy

Action: surgical procedure MAXO:0000004

Surgical treatment for early-stage invasive cervical cancer (IA2-IB2) includes removal of the uterus, parametria, and upper vagina, with pelvic lymphadenectomy. Fertility-sparing radical trachelectomy may be considered in select cases.

Chemoradiation

Action: radiation therapy MAXO:0000014

Agent: cisplatin ↗

Concurrent cisplatin-based chemotherapy with external beam radiation and brachytherapy is the standard treatment for locally advanced cervical cancer (stages IB3-IVA). Improves survival compared to radiation alone.

Pembrolizumab

Action: immunotherapy Ontology label: Immunotherapy NCIT:C15262

Agent: pembrolizumab ↗

PD-1 inhibitor approved for recurrent or metastatic cervical cancer with PD-L1 expression (CPS score of at least 1) in combination with chemotherapy, or as monotherapy in previously treated PD-L1 positive tumors.

🔬

Biochemical Markers

2

HPV DNA Testing

p16 Immunohistochemistry

{ }

Source YAML

click to show

name: Cervical Cancer
creation_date: '2026-01-26T02:55:13Z'
updated_date: '2026-05-08T18:54:20Z'
description: >-
  Cervical cancer is a malignancy arising from the epithelium of the uterine cervix,
  with the vast majority (greater than 95%) caused by persistent infection with
  high-risk human papillomavirus (HPV), primarily types 16 and 18. The viral
  oncoproteins E6 and E7 drive carcinogenesis by inactivating the tumor suppressors
  p53 and pRB, respectively. Cervical cancer is preventable through HPV vaccination
  and detectable at preinvasive stages through screening, making it a model for
  infection-driven cancer prevention.
categories:
- Gynecologic Malignancy
- Viral-Associated Cancer
- HPV-Related Cancer
parents:
- uterine cancer
has_subtypes:
- name: Squamous Cell Carcinoma
  description: >-
    The most common histologic type, accounting for approximately 70-80% of cases.
    Arises from the squamous epithelium of the ectocervix, typically at the
    transformation zone where squamous and glandular epithelia meet.
- name: Adenocarcinoma
  description: >-
    Accounts for 20-25% of cervical cancers. Arises from the glandular epithelium
    of the endocervical canal. Often HPV-18 associated. May be more difficult to
    detect by cytology screening.
- name: Adenosquamous Carcinoma
  description: >-
    Mixed tumors with both squamous and glandular differentiation. Generally
    associated with worse prognosis than pure squamous cell carcinoma.
infectious_agent:
- name: Human Papillomavirus (HPV)
  description: >-
    High-risk HPV types, particularly HPV-16 and HPV-18, cause greater than 95%
    of cervical cancers. HPV-16 is responsible for approximately 50% of cases
    and HPV-18 for approximately 20%. Persistent infection with high-risk types
    is necessary but not sufficient for cancer development.
  evidence:
  - reference: PMID:41503346
    reference_title: "Prevalence and genotype distribution of high-risk human papillomavirus infections among women in selected communities in the Philippines: Results of the defeat HPV study."
    supports: SUPPORT
    snippet: "Persistent infection with high-risk human papillomavirus (HR HPV) is the necessary cause of cervical cancer."
    explanation: "Supports HPV as the necessary causal agent for cervical cancer."
  infectious_agent_term:
    preferred_term: Human papillomavirus 16
    term:
      id: NCBITaxon:333760
      label: Human papillomavirus 16
pathophysiology:
- name: E6 Oncoprotein-Mediated p53 Degradation
  description: >-
    The HPV E6 oncoprotein binds to the cellular E3 ubiquitin ligase E6AP and
    targets p53 for proteasomal degradation. Loss of p53 function eliminates
    DNA damage checkpoints, allows cells with genomic instability to survive,
    and prevents apoptosis of infected cells.
  cell_types:
  - preferred_term: epithelial cell of cervix
    term:
      id: CL:0002535
      label: epithelial cell of cervix
  biological_processes:
  - preferred_term: proteasome-mediated ubiquitin-dependent protein catabolic process
    modifier: INCREASED
    term:
      id: GO:0043161
      label: proteasome-mediated ubiquitin-dependent protein catabolic process
  - preferred_term: apoptotic process
    modifier: DECREASED
    term:
      id: GO:0006915
      label: apoptotic process
  locations:
  - preferred_term: uterine cervix
    term:
      id: UBERON:0000002
      label: uterine cervix
  evidence:
  - reference: PMID:2175676
    reference_title: "The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: that bind p53 stimulate the degradation of p53.
    explanation: >-
      Classic mechanistic evidence shows high-risk HPV E6 promotes p53
      degradation, supporting p53 checkpoint loss as a central cervical cancer
      mechanism.
  downstream:
  - target: Loss of DNA Damage Response
    description: p53 degradation removes critical cell cycle checkpoints
  - target: Genomic Instability
    description: Cells with damaged DNA continue to proliferate
- name: Loss of DNA Damage Response
  description: >-
    E6-mediated degradation of p53 weakens DNA-damage checkpoint and apoptosis
    responses, allowing damaged cervical epithelial cells to survive instead
    of undergoing growth arrest or programmed cell death.
  biological_processes:
  - preferred_term: DNA damage response
    modifier: DECREASED
    term:
      id: GO:0006974
      label: DNA damage response
  - preferred_term: cell cycle checkpoint signaling
    modifier: DECREASED
    term:
      id: GO:0000075
      label: cell cycle checkpoint signaling
  evidence:
  - reference: PMID:2175676
    reference_title: "The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: p53 is ATP dependent and involves the ubiquitin-dependent protease system.
    explanation: >-
      p53 degradation provides direct mechanistic support for impaired
      p53-mediated DNA damage response and checkpoint control.
  downstream:
  - target: Genomic Instability
    description: Cells with unrepaired damage persist and acquire additional alterations
- name: Genomic Instability
  description: >-
    HPV integration and impaired checkpoint control are associated with
    structural genomic aberrations, supporting the accumulation of alterations
    that help drive malignant progression.
  biological_processes:
  - preferred_term: DNA damage response
    modifier: ABNORMAL
    term:
      id: GO:0006974
      label: DNA damage response
  evidence:
  - reference: PMID:28112728
    reference_title: "Integrated genomic and molecular characterization of cervical cancer."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: aberrations and increased target-gene expression.
    explanation: >-
      Human cervical tumor genomic data link HPV integration with structural
      aberrations, supporting genomic instability in HPV-driven carcinogenesis.
  downstream:
  - target: Cervical Intraepithelial Neoplasia Progression
    description: Genomic alterations contribute to progression from preinvasive lesions
- name: E7 Oncoprotein-Mediated pRB Inactivation
  description: >-
    The HPV E7 oncoprotein binds to and inactivates the retinoblastoma protein
    (pRB), releasing E2F transcription factors to drive uncontrolled cell cycle
    progression. E7 also targets pRB family members p107 and p130, and
    destabilizes pRB through proteasomal degradation.
  biological_processes:
  - preferred_term: G1/S transition of mitotic cell cycle
    modifier: ABNORMAL
    term:
      id: GO:0000082
      label: G1/S transition of mitotic cell cycle
  - preferred_term: cell cycle checkpoint signaling
    modifier: DECREASED
    term:
      id: GO:0000075
      label: cell cycle checkpoint signaling
  evidence:
  - reference: PMID:2537532
    reference_title: "The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: form similar complexes with p105-RB. Human papilloma virus-16 is found
    explanation: >-
      Classic biochemical evidence shows HPV16 E7 binds the retinoblastoma
      gene product, supporting pRB-pathway inactivation.
  downstream:
  - target: Uncontrolled Cell Proliferation
    description: E2F release drives S-phase entry independent of growth signals
- name: Uncontrolled Cell Proliferation
  description: >-
    E7 binding to pRB disrupts retinoblastoma-mediated cell-cycle restraint,
    enabling inappropriate S-phase entry and proliferation of HPV-transformed
    cervical epithelial cells.
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  - preferred_term: G1/S transition of mitotic cell cycle
    modifier: INCREASED
    term:
      id: GO:0000082
      label: G1/S transition of mitotic cell cycle
  evidence:
  - reference: PMID:2537532
    reference_title: "The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: implicate RB binding as a possible step in human papilloma
    explanation: >-
      RB binding by HPV16 E7 supports transformation through loss of RB-mediated
      cell-cycle control.
  downstream:
  - target: Cervical Intraepithelial Neoplasia Progression
    description: Persistent proliferative signaling contributes to preinvasive lesion progression
- name: HPV Genome Integration
  description: >-
    Integration of HPV DNA into the host genome disrupts the viral E2 gene,
    which normally represses E6/E7 expression. This results in constitutive
    overexpression of E6 and E7 oncoproteins, a critical step in malignant
    progression from CIN3 to invasive carcinoma.
  evidence:
  - reference: PMID:28112728
    reference_title: "Integrated genomic and molecular characterization of cervical cancer."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: aberrations and increased target-gene expression.
    explanation: TCGA confirmed near-universal HPV integration in HPV18-positive cervical cancers and frequent integration in HPV16-positive cancers, linked to host structural alterations and target-gene upregulation.
  biological_processes:
  - preferred_term: viral genome integration into host DNA
    term:
      id: GO:0044826
      label: viral genome integration into host DNA
  downstream:
  - target: Constitutive E6/E7 Expression
    description: Loss of E2 repression leads to unchecked oncoprotein production
- name: Constitutive E6/E7 Expression
  description: >-
    HPV integration-associated loss of viral regulatory control sustains
    expression of the E6 and E7 viral oncoproteins, feeding the p53 and pRB
    disruption arms of cervical carcinogenesis.
  evidence:
  - reference: PMID:28112728
    reference_title: "Integrated genomic and molecular characterization of cervical cancer."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: aberrations and increased target-gene expression.
    explanation: >-
      TCGA cervical tumor data support integration-associated increased target
      gene expression, consistent with persistent oncogene expression.
  - reference: PMID:2175676
    reference_title: "The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: one of two viral products expressed in HPV-associated cancers. E6 is an
    explanation: >-
      This establishes E6 as an expressed viral oncoprotein in HPV-associated
      cancers.
  downstream:
  - target: E6 Oncoprotein-Mediated p53 Degradation
    description: Sustained E6 expression drives p53 degradation
  - target: E7 Oncoprotein-Mediated pRB Inactivation
    description: Sustained E7 expression drives pRB inactivation
- name: Cervical Intraepithelial Neoplasia Progression
  description: >-
    HPV infection induces a spectrum of preinvasive lesions graded as CIN1,
    CIN2, and CIN3 (carcinoma in situ). Low-grade lesions (CIN1) often regress,
    while high-grade lesions (CIN2/3) have significant risk of progression to
    invasive carcinoma over 10-20 years if untreated.
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: PMID:12953088
    reference_title: Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Precursor lesions of the cervix persist longer and progress more
    explanation: >-
      A longitudinal HPV/CIN cohort supports oncogenic HPV-associated
      persistence and faster progression of cervical precursor lesions.
histopathology:
- name: Squamous Cell Carcinoma
  finding_term:
    preferred_term: Squamous Cell Carcinoma
    term:
      id: NCIT:C2929
      label: Squamous Cell Carcinoma
  frequency: VERY_FREQUENT
  description: Squamous cell carcinoma is the most common malignant cervical tumor.
  evidence:
  - reference: PMID:14690308
    reference_title: "Pathology of cervical cancer."
    supports: SUPPORT
    snippet: "Squamous cell carcinoma is the most common malignant cervical tumor"
    explanation: Abstract reports squamous cell carcinoma as the most common malignant cervical tumor.

phenotypes:
- category: Gynecologic
  name: Abnormal Vaginal Bleeding
  frequency: FREQUENT
  diagnostic: true
  description: >-
    The most common presenting symptom, including postcoital bleeding,
    intermenstrual bleeding, or postmenopausal bleeding. Often the first sign
    of invasive disease.
  phenotype_term:
    preferred_term: Metrorrhagia
    term:
      id: HP:0100608
      label: Metrorrhagia
  evidence:
  - reference: PMID:29794500
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Common symptoms were abnormal vaginal bleeding, low abdominal pain, and malodorous vaginal discharge reported among 75.8%, 66.4%, and 39.6% of cases, respectively."
    explanation: >-
      Retrospective review of 149 cervical cancer patients in Botswana
      identifies abnormal vaginal bleeding as the most common
      presenting symptom (75.8%), supporting its classification as a
      frequent diagnostic phenotype.
- category: Gynecologic
  name: Vaginal Discharge
  frequency: FREQUENT
  description: >-
    Watery, mucoid, or blood-tinged vaginal discharge may occur, sometimes
    with foul odor in advanced cases due to tumor necrosis.
  notes: >-
    No suitable specific HP term for vaginal discharge was identified in the
    current ontology build; phenotype captured clinically as abnormal genital
    tract secretion.
  evidence:
  - reference: PMID:29794500
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Common symptoms were abnormal vaginal bleeding, low abdominal pain, and malodorous vaginal discharge reported among 75.8%, 66.4%, and 39.6% of cases, respectively."
    explanation: >-
      Same Botswana retrospective review reports malodorous vaginal
      discharge in 39.6% of cervical cancer cases, supporting its
      classification as a frequent presenting symptom.
- category: Pelvic
  name: Pelvic Pain
  frequency: FREQUENT
  description: >-
    Pelvic pain typically indicates locally advanced disease with parametrial
    invasion, pelvic sidewall involvement, or nerve compression.
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
  evidence:
  - reference: PMID:29794500
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Common symptoms were abnormal vaginal bleeding, low abdominal pain, and malodorous vaginal discharge reported among 75.8%, 66.4%, and 39.6% of cases, respectively."
    explanation: >-
      Low abdominal pain was reported in 66.4% of cervical cancer
      patients in this Botswana cohort, with the same study identifying
      low abdominal pain as a significant predictor of locally
      advanced disease at presentation.
- category: Urinary
  name: Hematuria
  frequency: FREQUENT
  description: >-
    Hematuria is a frequent urinary manifestation in advanced cervical cancer
    and may reflect bladder mucosal involvement.
  phenotype_term:
    preferred_term: Hematuria
    term:
      id: HP:0000790
      label: Hematuria
  evidence:
  - reference: PMID:23244084
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A total of 130 were patients included, 54 of which (41.5%) had hematuria."
    explanation: >-
      Prospective study of 130 newly diagnosed cervical cancer
      patients quantifies hematuria prevalence (41.5%), with hematuria
      shown to be a sensitive screening test for urinary bladder
      mucosal infiltration in advanced cervical cancer, supporting
      classification as a frequent phenotype.
biochemical:
- name: HPV DNA Testing
  notes: >-
    Detection of high-risk HPV DNA by PCR or hybrid capture is more sensitive
    than cytology for detecting high-grade lesions. HPV testing is increasingly
    used as primary screening in cervical cancer prevention programs.
- name: p16 Immunohistochemistry
  notes: >-
    Overexpression of p16INK4a is a surrogate marker for HPV E7 activity, as
    E7-mediated pRB inactivation causes compensatory p16 upregulation. Diffuse
    block-positive p16 staining helps confirm HPV-related high-grade lesions.
genetic:
- name: TP53
  association: Inactivated by E6 Oncoprotein
  notes: >-
    Rather than somatic mutation, p53 function is lost through E6-mediated
    degradation in HPV-positive cervical cancer. Rare HPV-negative cervical
    cancers may harbor TP53 mutations.
- name: PIK3CA
  association: Somatic Mutations
  notes: >-
    PIK3CA mutations occur in approximately 25-35% of cervical cancers,
    activating PI3K/AKT/mTOR signaling. May represent a therapeutic target.
diagnosis:
- name: HPV DNA screening and genotyping
  description: >-
    High-risk HPV DNA detection and genotyping support cervical cancer
    prevention and diagnostic triage by identifying persistent oncogenic HPV
    infection, the necessary causal exposure for cervical carcinogenesis.
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: MAXO:0000487
      label: clinical assessment
  markers: high-risk HPV DNA
  results: Detection of high-risk HPV genotypes in cervical samples.
  evidence:
  - reference: PMID:41503346
    reference_title: "Prevalence and genotype distribution of high-risk human papillomavirus infections among women in selected communities in the Philippines: Results of the defeat HPV study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Persistent infection with high-risk human papillomavirus (HR HPV) is the necessary cause of cervical cancer."
    explanation: This supports high-risk HPV detection as a central diagnostic and screening target.
  - reference: PMID:41503346
    reference_title: "Prevalence and genotype distribution of high-risk human papillomavirus infections among women in selected communities in the Philippines: Results of the defeat HPV study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cervical swabs were collected, and the extracted DNA were analyzed
      for HPV genotyping through a commercial multiplex real-time PCR
      assay kit.
    explanation: This supports HPV DNA genotyping from cervical samples as an evidence-backed diagnostic method.
- name: Histopathologic confirmation of cervical malignancy
  description: >-
    Tissue diagnosis classifies cervical cancer histology, including squamous
    cell carcinoma and adenocarcinoma, and informs treatment planning.
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: MAXO:0000487
      label: clinical assessment
  results: Malignant cervical tumor histology.
  evidence:
  - reference: PMID:14690308
    reference_title: "Pathology of cervical cancer."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This article discusses the epidemiology and pathogenesis of the
      squamous cell carcinoma, its clinical and histologic features,
      including microinvasive carcinoma, its histologic grade, and
      variant tumors.
    explanation: This pathology review supports histologic characterization as part of cervical cancer diagnosis.
treatments:
- name: HPV Vaccination
  description: >-
    Prophylactic vaccination against HPV-16, 18, and other high-risk types
    prevents infection and subsequent development of cervical cancer and
    precancerous lesions. Most effective when administered before sexual debut.
  treatment_term:
    preferred_term: vaccination
    term:
      id: MAXO:0001017
      label: vaccination
- name: Cone Biopsy/LEEP
  description: >-
    Loop electrosurgical excision procedure (LEEP) or cold knife cone biopsy
    for treatment of high-grade cervical intraepithelial neoplasia (CIN2/3).
    Allows fertility preservation while treating preinvasive disease.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: Radical Hysterectomy
  description: >-
    Surgical treatment for early-stage invasive cervical cancer (IA2-IB2)
    includes removal of the uterus, parametria, and upper vagina, with pelvic
    lymphadenectomy. Fertility-sparing radical trachelectomy may be considered
    in select cases.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: Chemoradiation
  description: >-
    Concurrent cisplatin-based chemotherapy with external beam radiation and
    brachytherapy is the standard treatment for locally advanced cervical
    cancer (stages IB3-IVA). Improves survival compared to radiation alone.
  treatment_term:
    preferred_term: radiation therapy
    term:
      id: MAXO:0000014
      label: radiation therapy
    therapeutic_agent:
    - preferred_term: cisplatin
      term:
        id: NCIT:C376
        label: Cisplatin
- name: Pembrolizumab
  description: >-
    PD-1 inhibitor approved for recurrent or metastatic cervical cancer with
    PD-L1 expression (CPS score of at least 1) in combination with chemotherapy,
    or as monotherapy in previously treated PD-L1 positive tumors.
  treatment_term:
    preferred_term: immunotherapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
    therapeutic_agent:
    - preferred_term: pembrolizumab
      term:
        id: NCIT:C106432
        label: Pembrolizumab
disease_term:
  preferred_term: cervical cancer
  term:
    id: MONDO:0002974
    label: cervical cancer

classifications:
  icdo_morphology:
    classification_value: Carcinoma
  harrisons_chapter:
  - classification_value: cancer
  - classification_value: solid tumor
references:
- reference: DOI:10.1007/s12094-024-03604-3
  title: SEOM-GEICO Clinical Guidelines on cervical cancer (2023)
  found_in:
  - Cervical_Cancer-deep-research-falcon.md
  findings:
  - statement: Cervical cancer (CC) is the fourth most common cancer and the fourth leading cause of mortality in women worldwide.
    supporting_text: Cervical cancer (CC) is the fourth most common cancer and the fourth leading cause of mortality in women worldwide.
    evidence:
    - reference: DOI:10.1007/s12094-024-03604-3
      reference_title: SEOM-GEICO Clinical Guidelines on cervical cancer (2023)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Cervical cancer (CC) is the fourth most common cancer and the fourth leading cause of mortality in women worldwide.
      explanation: Deep research cited this publication as relevant literature for Cervical Cancer.
- reference: DOI:10.1038/s41591-024-03014-6
  title: Cervical cancer screening using DNA methylation triage in a real-world population
  found_in:
  - Cervical_Cancer-deep-research-falcon.md
  findings:
  - statement: Cervical cancer (CC) screening in women comprises human papillomavirus (HPV) testing followed by cytology triage of positive cases.
    supporting_text: Cervical cancer (CC) screening in women comprises human papillomavirus (HPV) testing followed by cytology triage of positive cases.
    evidence:
    - reference: DOI:10.1038/s41591-024-03014-6
      reference_title: Cervical cancer screening using DNA methylation triage in a real-world population
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Cervical cancer (CC) screening in women comprises human papillomavirus (HPV) testing followed by cytology triage of positive cases.
      explanation: Deep research cited this publication as relevant literature for Cervical Cancer.
- reference: DOI:10.20517/cdr.2023.120
  title: The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer
  found_in:
  - Cervical_Cancer-deep-research-falcon.md
  findings:
  - statement: The introduction of immune checkpoint inhibitors (ICIs) has revolutionized the treatment landscape for numerous tumor types, including cervical and endometrial cancers.
    supporting_text: The introduction of immune checkpoint inhibitors (ICIs) has revolutionized the treatment landscape for numerous tumor types, including cervical and endometrial cancers.
    evidence:
    - reference: DOI:10.20517/cdr.2023.120
      reference_title: The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The introduction of immune checkpoint inhibitors (ICIs) has revolutionized the treatment landscape for numerous tumor types, including cervical and endometrial cancers.
      explanation: Deep research cited this publication as relevant literature for Cervical Cancer.
- reference: DOI:10.3322/caac.21834
  title: 'Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries'
  found_in:
  - Cervical_Cancer-deep-research-falcon.md
  findings:
  - statement: This article presents global cancer statistics by world region for the year 2022 based on updated estimates from the International Agency for Research on Cancer (IARC).
    supporting_text: This article presents global cancer statistics by world region for the year 2022 based on updated estimates from the International Agency for Research on Cancer (IARC).
    evidence:
    - reference: DOI:10.3322/caac.21834
      reference_title: 'Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: This article presents global cancer statistics by world region for the year 2022 based on updated estimates from the International Agency for Research on Cancer (IARC).
      explanation: Deep research cited this publication as relevant literature for Cervical Cancer.
- reference: DOI:10.3390/cancers16040775
  title: 'The Role of Imaging in Cervical Cancer Staging: ESGO/ESTRO/ESP Guidelines (Update 2023)'
  found_in:
  - Cervical_Cancer-deep-research-falcon.md
  findings:
  - statement: 'The Role of Imaging in Cervical Cancer Staging: ESGO/ESTRO/ESP Guidelines (Update 2023)'
    supporting_text: Following the European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) joint guidelines (2018) for the management of patients with cervical cancer, treatment decisions should be guided by modern imaging techniques.
    evidence:
    - reference: DOI:10.3390/cancers16040775
      reference_title: 'The Role of Imaging in Cervical Cancer Staging: ESGO/ESTRO/ESP Guidelines (Update 2023)'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Following the European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) joint guidelines (2018) for the management of patients with cervical cancer, treatment decisions should be guided by modern imaging techniques.
      explanation: Deep research cited this publication as relevant literature for Cervical Cancer.
- reference: DOI:10.3390/curroncol33010048
  title: 'Advances in Screening, Immunotherapy, Targeted Agents, and Precision Surgery in Cervical Cancer: A Comprehensive Clinical Review (2018–2025)'
  found_in:
  - Cervical_Cancer-deep-research-falcon.md
  findings:
  - statement: Cervical cancer remains a significant global health burden, disproportionately affecting women in low- and middle-income countries despite being preventable.
    supporting_text: Cervical cancer remains a significant global health burden, disproportionately affecting women in low- and middle-income countries despite being preventable.
    evidence:
    - reference: DOI:10.3390/curroncol33010048
      reference_title: 'Advances in Screening, Immunotherapy, Targeted Agents, and Precision Surgery in Cervical Cancer: A Comprehensive Clinical Review (2018–2025)'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Cervical cancer remains a significant global health burden, disproportionately affecting women in low- and middle-income countries despite being preventable.
      explanation: Deep research cited this publication as relevant literature for Cervical Cancer.
- reference: DOI:10.3390/jcm13154351
  title: The Polish Society of Gynecological Oncology Guidelines for the Diagnosis and Treatment of Cervical Cancer (v2024.0)
  found_in:
  - Cervical_Cancer-deep-research-falcon.md
  findings:
  - statement: The Polish Society of Gynecological Oncology Guidelines for the Diagnosis and Treatment of Cervical Cancer (v2024.0)
    supporting_text: Recent publications underscore the need for updated recommendations addressing less radical surgery for <2 cm tumors, induction chemotherapy, or immunotherapy for locally advanced stages of cervical cancer, as well as for the systemic therapy for recurrent or metastatic cervical cancer.
    evidence:
    - reference: DOI:10.3390/jcm13154351
      reference_title: The Polish Society of Gynecological Oncology Guidelines for the Diagnosis and Treatment of Cervical Cancer (v2024.0)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Recent publications underscore the need for updated recommendations addressing less radical surgery for <2 cm tumors, induction chemotherapy, or immunotherapy for locally advanced stages of cervical cancer, as well as for the systemic therapy for recurrent or metastatic cervical cancer.
      explanation: Deep research cited this publication as relevant literature for Cervical Cancer.

📚

References & Deep Research

References

7

DOI:10.1007/s12094-024-03604-3

SEOM-GEICO Clinical Guidelines on cervical cancer (2023)

1 finding

Cervical cancer (CC) is the fourth most common cancer and the fourth leading cause of mortality in women worldwide.

"Cervical cancer (CC) is the fourth most common cancer and the fourth leading cause of mortality in women worldwide."

Show evidence (1 reference)

DOI:10.1007/s12094-024-03604-3 SUPPORT Other

"Cervical cancer (CC) is the fourth most common cancer and the fourth leading cause of mortality in women worldwide."

Deep research cited this publication as relevant literature for Cervical Cancer.

DOI:10.1038/s41591-024-03014-6

Cervical cancer screening using DNA methylation triage in a real-world population

1 finding

Cervical cancer (CC) screening in women comprises human papillomavirus (HPV) testing followed by cytology triage of positive cases.

"Cervical cancer (CC) screening in women comprises human papillomavirus (HPV) testing followed by cytology triage of positive cases."

Show evidence (1 reference)

DOI:10.1038/s41591-024-03014-6 SUPPORT Human Clinical

"Cervical cancer (CC) screening in women comprises human papillomavirus (HPV) testing followed by cytology triage of positive cases."

Deep research cited this publication as relevant literature for Cervical Cancer.

DOI:10.20517/cdr.2023.120

The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer

1 finding

The introduction of immune checkpoint inhibitors (ICIs) has revolutionized the treatment landscape for numerous tumor types, including cervical and endometrial cancers.

"The introduction of immune checkpoint inhibitors (ICIs) has revolutionized the treatment landscape for numerous tumor types, including cervical and endometrial cancers."

Show evidence (1 reference)

DOI:10.20517/cdr.2023.120 SUPPORT Human Clinical

"The introduction of immune checkpoint inhibitors (ICIs) has revolutionized the treatment landscape for numerous tumor types, including cervical and endometrial cancers."

Deep research cited this publication as relevant literature for Cervical Cancer.

DOI:10.3322/caac.21834

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

1 finding

This article presents global cancer statistics by world region for the year 2022 based on updated estimates from the International Agency for Research on Cancer (IARC).

"This article presents global cancer statistics by world region for the year 2022 based on updated estimates from the International Agency for Research on Cancer (IARC)."

Show evidence (1 reference)

DOI:10.3322/caac.21834 SUPPORT Human Clinical

"This article presents global cancer statistics by world region for the year 2022 based on updated estimates from the International Agency for Research on Cancer (IARC)."

Deep research cited this publication as relevant literature for Cervical Cancer.

DOI:10.3390/cancers16040775

The Role of Imaging in Cervical Cancer Staging: ESGO/ESTRO/ESP Guidelines (Update 2023)

1 finding

The Role of Imaging in Cervical Cancer Staging: ESGO/ESTRO/ESP Guidelines (Update 2023)

"Following the European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) joint guidelines (2018) for the management of patients with cervical cancer, treatment decisions should be guided by modern..."

Show evidence (1 reference)

DOI:10.3390/cancers16040775 SUPPORT Other

"Following the European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) joint guidelines (2018) for the management of patients with cervical cancer, treatment decisions should be guided by modern..."

Deep research cited this publication as relevant literature for Cervical Cancer.

DOI:10.3390/curroncol33010048

Advances in Screening, Immunotherapy, Targeted Agents, and Precision Surgery in Cervical Cancer: A Comprehensive Clinical Review (2018–2025)

1 finding

Cervical cancer remains a significant global health burden, disproportionately affecting women in low- and middle-income countries despite being preventable.

"Cervical cancer remains a significant global health burden, disproportionately affecting women in low- and middle-income countries despite being preventable."

Show evidence (1 reference)

DOI:10.3390/curroncol33010048 SUPPORT Human Clinical

"Cervical cancer remains a significant global health burden, disproportionately affecting women in low- and middle-income countries despite being preventable."

Deep research cited this publication as relevant literature for Cervical Cancer.

DOI:10.3390/jcm13154351

The Polish Society of Gynecological Oncology Guidelines for the Diagnosis and Treatment of Cervical Cancer (v2024.0)

1 finding

The Polish Society of Gynecological Oncology Guidelines for the Diagnosis and Treatment of Cervical Cancer (v2024.0)

"Recent publications underscore the need for updated recommendations addressing less radical surgery for <2 cm tumors, induction chemotherapy, or immunotherapy for locally advanced stages of cervical cancer, as well as for the systemic therapy for recurrent or metastatic cervical cancer."

Show evidence (1 reference)

DOI:10.3390/jcm13154351 SUPPORT Other

"Recent publications underscore the need for updated recommendations addressing less radical surgery for <2 cm tumors, induction chemotherapy, or immunotherapy for locally advanced stages of cervical cancer, as well as for the systemic therapy for recurrent or metastatic cervical cancer."

Deep research cited this publication as relevant literature for Cervical Cancer.

Deep Research

1

Falcon ▸

Key 2023–2024 Developments Highlighted by the Retrieved Evidence

Edison Scientific Literature 40 citations 2026-05-08T11:25:50.219834

1. Disease Information

1.1 Concise overview

Cervical cancer is a malignancy arising from the cervix uteri, typically preceded by detectable precursor lesions (e.g., high-grade CIN) and strongly driven by persistent infection with oncogenic (“high-risk”) human papillomavirus (HPV). Reviews emphasize that the disease is largely preventable through HPV vaccination and effective screening programs. (goldstein2024thefutureof pages 1-2, manso2024seomgeicoclinicalguidelines pages 1-2)

1.2 Common synonyms / alternative names (not exhaustive)

Common clinical labels include: “cancer of the cervix,” “cervical carcinoma,” “cervix uteri cancer.” These synonyms were not enumerated in the retrieved sources and are provided as standard clinical terminology (unsourced in-tool).

1.3 Evidence provenance

The information presented here is derived from aggregated disease-level resources and peer‑reviewed studies/guidelines (GLOBOCAN analyses, international guidelines, and population-based implementation studies), rather than individual patient EHR extracts. (bray2024globalcancerstatistics pages 5-6, teixeira2024transitionfromopportunistic pages 1-2, fischerova2024theroleof pages 1-2, manso2024seomgeicoclinicalguidelines pages 1-2)

2. Etiology

2.1 Primary causal factors

Persistent high-risk HPV infection is the dominant causal factor in cervical cancer. - A 2024 screening-technology review states that “over 95% of cervical cancer cases are attributable to HPV” and that HPV‑16/18 account for ~71% of global cases. (goldstein2024thefutureof pages 1-2) - Mechanistically, reviews describe HPV oncogenesis via viral oncoproteins E6/E7, including inactivation of tumor suppressors p53 and Rb, and note the role of HPV genome integration during progression. (nagdev2026advancesinscreening pages 2-4)

2.2 Risk factors and co-factors (evidence available in retrieved sources)

The retrieved evidence emphasizes population-level and biologic drivers rather than a comprehensive quantified list of co-factors. - Multi-type HPV infection is described as clinically relevant; one review reports co-infection prevalence ranges ~18.5–46% among HPV-positive women (context: HPV infection epidemiology and screening triage). (goldstein2024thefutureof pages 1-2) - Broader prevention context: the GLOBOCAN 2022 analysis describes HPV as a “necessary (but not sufficient)” cause and highlights elimination-strategy targets and screening ages (35 and 45), implying programmatic focus on preventing persistent infection and progression. (bray2024globalcancerstatistics pages 26-26)

2.3 Protective factors

Evidence in retrieved sources supports: - HPV vaccination and screening as key protective interventions; high-income countries with HPV vaccination and screening have experienced “dramatic reductions” in incidence in guideline summaries. (manso2024seomgeicoclinicalguidelines pages 1-2)

2.4 Gene–environment interactions

Specific gene–environment interaction findings were not identified in the retrieved sources for this run.

3. Phenotypes (clinical presentation)

The retrieved sources for this run focus primarily on screening, staging, imaging, and systemic therapy rather than symptom prevalence. As a result: - Comprehensive phenotype lists, frequencies, and quality-of-life impacts with primary citations could not be extracted. - HPO term suggestions are therefore not provided as evidence-backed entries in this run.

4. Genetic / Molecular Information

4.1 Key molecular concepts (HPV-driven carcinogenesis)

Recent reviews reiterate HPV-driven transformation mechanisms and host genomic/epigenetic alterations: - HPV E6/E7 perturbation of p53/Rb is highlighted as a core axis for malignant transformation. (nagdev2026advancesinscreening pages 2-4) - Reviews summarize that somatic alterations (including PIK3CA mutations and APOBEC signatures) are recurrent in cervical cancer, providing a rationale for targeted therapy exploration and biomarker-guided approaches. (nagdev2026advancesinscreening pages 2-4)

4.2 Epigenetics and methylation biomarkers (2024 primary research)

A major 2024 real-world screening study evaluated DNA methylation triage: - WID-qCIN assay measures methylation of DPP6, RALYL, GSX1 in HPV-positive screening samples. (schreiberhuber2024cervicalcancerscreening pages 1-2, schreiberhuber2024cervicalcancerscreening pages 2-3) - In 28,017 screened women (Stockholm; ≥30 years; 2,377 HPV-positive), WID-qCIN + HPV16/18 detected 93.4% of CIN3 and 100% of invasive cervical cancers. (schreiberhuber2024cervicalcancerscreening pages 1-2, schreiberhuber2024cervicalcancerscreening pages 2-3)

5. Environmental Information

The retrieved sources emphasize infectious etiology and screening-system factors rather than detailed chemical/toxin exposures. Infectious agent: - High-risk HPV is the principal infectious driver. (goldstein2024thefutureof pages 1-2, manso2024seomgeicoclinicalguidelines pages 1-2)

6. Mechanism / Pathophysiology

6.1 Causal chain (high-level)

High-risk HPV infection of cervical epithelium; persistent infection over years is a prerequisite for progression. (goldstein2024thefutureof pages 1-2, nagdev2026advancesinscreening pages 2-4)
Viral genome integration and expression of E6/E7 oncoproteins drives dysregulated cell-cycle control (p53/Rb pathway interference) and supports malignant transformation. (nagdev2026advancesinscreening pages 2-4)
Accumulation of host genomic/epigenetic alterations and tumor microenvironment remodeling contributes to invasion and metastasis, motivating biomarker-driven and immunotherapy approaches. (nagdev2026advancesinscreening pages 2-4)

6.2 Immune system involvement and implications

Immune checkpoint blockade has become clinically important in advanced disease, indicating that immune evasion and immune contexture are therapeutically actionable in a subset of patients. (martinezcannon2024theevolvingrole pages 1-3, manso2024seomgeicoclinicalguidelines pages 1-2)

7. Anatomical Structures Affected

Primary site: cervix uteri. (Implied throughout cervical-cancer-focused guidelines and imaging papers; explicit ontology mapping not retrieved.) (fischerova2024theroleof pages 1-2)

Staging spread assessed by imaging: parametrial extension; invasion of bladder/rectal wall; pelvic and paraaortic nodal metastases; distant metastases (lung, liver, bone, peritoneum). (fischerova2024theroleof pages 7-8, fischerova2024theroleof pages 26-27, fischerova2024theroleof pages 6-7)

8. Temporal Development

The retrieved sources describe long preclinical windows enabling prevention: - Screening and prevention frameworks emphasize that effective programs can detect precancers and early cancers and shift stage distribution toward earlier disease. A Brazilian organized HPV DNA screening program reported earlier-stage detection (majority Stage I) compared with prior cytology-era advanced-stage predominance. (teixeira2024transitionfromopportunistic pages 1-2)

9. Inheritance and Population

9.1 Epidemiology (recent authoritative statistics)

Global burden (GLOBOCAN 2022; published 2024): - 661,021 new cases and 348,189 deaths worldwide in 2022 (Table 1, cervix uteri). (bray2024globalcancerstatistics pages 5-6)

Disparities by development level (rates): - GLOBOCAN 2022 analysis reports higher incidence and mortality in “transitioning” vs “transitioned” countries (incidence 19.3 vs 12.1 per 100,000; mortality 12.4 vs 4.8 per 100,000). (bray2024globalcancerstatistics pages 26-26)

9.2 Sex ratio

Cervical cancer occurs in individuals with a cervix; sex ratio data were not extracted from retrieved sources in this run.

10. Diagnostics

10.1 Screening tests and triage (recent advances)

HPV-based screening (systems and implementation): - A 2024 review highlights emerging approaches including rapid/low-cost HPV testing, digital colposcopy with AI interpretation, DNA methylation assays, and dual-stain cytology. (goldstein2024thefutureof pages 1-2)

Real-world methylation triage (Nature Medicine 2024): - In HPV-positive samples, WID-qCIN/HPV16/18 improved triage efficiency: cytology triage would require 4.1 colposcopy referrals per CIN2+ vs 2.4 referrals per CIN2+ for WID-qCIN/HPV16/18 over follow-up. (schreiberhuber2024cervicalcancerscreening pages 1-2, schreiberhuber2024cervicalcancerscreening pages 4-5) - Visual evidence: Table summarizing colposcopy referral efficiency and detection performance is available from the paper. (schreiberhuber2024cervicalcancerscreening media 23da8e40)

10.2 Imaging and staging (ESGO/ESTRO/ESP update 2023; published 2024)

Modern guidelines incorporate imaging into staging and treatment planning: - Transvaginal/transrectal ultrasound or pelvic MRI is recommended for local staging; ultrasound can be a valid alternative to MRI in expert hands. (fischerova2024theroleof pages 1-2) - For early-stage tumors (T1a–T2a1 excluding T1b3) with negative nodes on ultrasound/MRI, surgicopathological staging is recommended because imaging has limited sensitivity for small-volume nodal disease. (fischerova2024theroleof pages 1-2) - For locally advanced disease or suspicious nodes, contrast-enhanced CT or FDG PET/CT is recommended for extrapelvic spread assessment; the guideline emphasizes high specificity but limited sensitivity for micrometastases across modalities. (fischerova2024theroleof pages 26-27)

11. Outcome / Prognosis

The retrieved evidence base in this run emphasizes stage shift through screening and survival improvements in advanced disease trials.

11.1 Screening-associated stage shift (population implementation)

In the PREVENTIVO organized HPV DNA screening program in Brazil: - 29 cancers were detected with 83% Stage I; in the prior opportunistic cytology period, 67% were advanced stage. (teixeira2024transitionfromopportunistic pages 1-2)

11.2 Advanced/recurrent metastatic disease outcomes (selected trial outcomes as summarized in authoritative reviews)

KEYNOTE-826 (pembrolizumab + platinum-taxane ± bevacizumab, first line): median OS 26.4 vs 16.8 months (review table extraction). (nagdev2026advancesinscreening pages 13-15)
EMPOWER-Cervical 1 (cemiplimab vs chemotherapy after platinum): median OS 12.0 vs 8.5 months; ORR 16.4% vs 6.3% reported in a 2024 ICI review. (martinezcannon2024theevolvingrole pages 1-3)
innovaTV-301 (tisotumab vedotin vs chemotherapy): median OS 11.5 vs 9.5 months and median PFS 4.2 vs 2.9 months (HR 0.67; p<0.0001) as summarized in a comprehensive review table. (nagdev2026advancesinscreening pages 13-15)

12. Treatment

12.1 Guideline-based treatment framework (2024 European/Spanish and national guidance)

Early-stage disease: managed primarily with surgery or radiotherapy; fertility-sparing approaches are used in selected low-risk early disease. (manso2024seomgeicoclinicalguidelines pages 1-2, manso2024seomgeicoclinicalguidelines pages 4-5)
Locally advanced disease: standard backbone is concurrent chemoradiotherapy (CCRT/CRT) followed by brachytherapy. (sznurkowski2024thepolishsociety pages 1-2, manso2024seomgeicoclinicalguidelines pages 1-2)

12.2 Systemic therapy and immunotherapy integration

The SEOM-GEICO guideline notes that immunotherapy has significantly improved OS in recurrent/metastatic disease when added to chemotherapy (± bevacizumab) in first line and as monotherapy after platinum in second line. (manso2024seomgeicoclinicalguidelines pages 1-2)
The Polish PSGO guideline (v2024.0) describes PD‑L1 testing to select pembrolizumab candidates and references immunotherapy incorporation for higher-risk locally advanced disease (pembrolizumab with CCRT and maintenance). (sznurkowski2024thepolishsociety pages 1-2)

12.3 Targeted therapy / ADC

Reviews highlight tisotumab vedotin (tissue factor–directed ADC) as a preferred later-line option in recurrent/metastatic disease, with characteristic toxicities including ocular events. (nagdev2026advancesinscreening pages 13-15)

12.4 MAXO (Medical Action Ontology) suggestions (non-exhaustive; ontology IDs not retrieved)

HPV vaccination; cervical cancer screening; HPV DNA testing; colposcopy; conization; hysterectomy; radiotherapy; brachytherapy; concurrent chemoradiotherapy; immune checkpoint inhibitor therapy; antibody–drug conjugate therapy.

13. Prevention

13.1 Primary prevention

HPV vaccination is emphasized across guidelines/reviews as central to prevention and elimination efforts. (goldstein2024thefutureof pages 1-2, manso2024seomgeicoclinicalguidelines pages 1-2)

13.2 Secondary prevention (screening)

HPV-based screening and effective triage are central; a major 2024 review highlights self-sampling, AI-assisted colposcopy, methylation, and other approaches to improve detection and risk stratification. (goldstein2024thefutureof pages 1-2)
GLOBOCAN-related discussion references elimination-strategy screening targets at ages 35 and 45 and emphasizes improving participation (including self-sampling). (bray2024globalcancerstatistics pages 26-26)

13.3 Real-world implementation example (organized screening)

Brazil’s PREVENTIVO program shows feasibility of switching from opportunistic cytology to organized HPV DNA testing, with coverage 58.7% (or 77.8% excluding pandemic months) and improved early-stage detection. (teixeira2024transitionfromopportunistic pages 1-2, teixeira2024transitionfromopportunistic pages 2-4)

14. Other Species / Natural Disease

Not addressed in the retrieved sources for this run.

15. Model Organisms

Model-organism and experimental-system details (e.g., HPV transgenic mice, organoids) were not captured in the retrieved sources excerpted in this run; therefore, evidence-backed model summaries are not provided.

Key 2023–2024 Developments Highlighted by the Retrieved Evidence

Updated global burden quantification (2024 publication of GLOBOCAN 2022 statistics) with explicit 2022 cervical cancer incidence/mortality counts. (bray2024globalcancerstatistics pages 5-6)
Real-world validation of DNA methylation triage (WID-qCIN) demonstrating high CIN3 and invasive-cancer detection and improved colposcopy efficiency vs cytology triage (Nature Medicine 2024). (schreiberhuber2024cervicalcancerscreening pages 1-2, schreiberhuber2024cervicalcancerscreening media 23da8e40)
Health-system implementation evidence for organized HPV DNA screening showing improved coverage, diagnostic follow-through, and earlier-stage cancer detection (Scientific Reports 2024). (teixeira2024transitionfromopportunistic pages 1-2)
Imaging/staging guidance (ESGO/ESTRO/ESP update 2023; published 2024) reinforcing ultrasound/MRI for local staging and PET/CT/CT for extrapelvic assessment, with explicit discussion of sensitivity limits for micrometastases. (fischerova2024theroleof pages 1-2, fischerova2024theroleof pages 26-27)
Therapy landscape consolidation in guidelines and reviews: integration of immune checkpoint blockade (pembrolizumab; cemiplimab) and ADCs (tisotumab vedotin) into recurrent/metastatic management frameworks. (manso2024seomgeicoclinicalguidelines pages 1-2, martinezcannon2024theevolvingrole pages 1-3, nagdev2026advancesinscreening pages 13-15)

URLs and publication dates (where available in retrieved sources)

Bray et al. “Global cancer statistics 2022…” CA Cancer J Clin Apr 2024. https://doi.org/10.3322/caac.21834 (bray2024globalcancerstatistics pages 5-6)
Schreiberhuber et al. “Cervical cancer screening using DNA methylation triage…” Nature Medicine Jun 2024. https://doi.org/10.1038/s41591-024-03014-6 (schreiberhuber2024cervicalcancerscreening pages 1-2)
Teixeira et al. “Transition… organized screening… DNA-HPV testing…” Scientific Reports Sep 2024. https://doi.org/10.1038/s41598-024-71735-2 (teixeira2024transitionfromopportunistic pages 1-2)
Fischerova et al. “The Role of Imaging in Cervical Cancer Staging: ESGO/ESTRO/ESP Guidelines (Update 2023)” Cancers Feb 2024. https://doi.org/10.3390/cancers16040775 (fischerova2024theroleof pages 1-2)
Manso et al. “SEOM-GEICO Clinical Guidelines on cervical cancer (2023)” Clin Transl Oncol Aug 2024. https://doi.org/10.1007/s12094-024-03604-3 (manso2024seomgeicoclinicalguidelines pages 1-2)
Goldstein et al. “The Future of Cervical Cancer Screening” Int J Women’s Health Oct 2024. https://doi.org/10.2147/IJWH.S474571 (goldstein2024thefutureof pages 1-2)

References

(bray2024globalcancerstatistics pages 5-6): Freddie Bray, Mathieu Laversanne, Hyuna Sung, Jacques Ferlay, Rebecca L. Siegel, Isabelle Soerjomataram, and Ahmedin Jemal. Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74:229-263, Apr 2024. URL: https://doi.org/10.3322/caac.21834, doi:10.3322/caac.21834. This article has 35815 citations and is from a domain leading peer-reviewed journal.
(goldstein2024thefutureof pages 1-2): Amelia R Goldstein, Mallory Gersh, Gabriela Skovronsky, and Chailee Moss. The future of cervical cancer screening. International Journal of Women's Health, 16:1715-1731, Oct 2024. URL: https://doi.org/10.2147/ijwh.s474571, doi:10.2147/ijwh.s474571. This article has 43 citations and is from a peer-reviewed journal.
(manso2024seomgeicoclinicalguidelines pages 1-2): Luis Manso, Avinash Ramchandani-Vaswani, Ignacio Romero, Luisa Sánchez-Lorenzo, María José Bermejo-Pérez, Purificación Estévez-García, Lorena Fariña-Madrid, Yolanda García García, Marta Gil-Martin, and María Quindós. Seom-geico clinical guidelines on cervical cancer (2023). Clinical & Translational Oncology, 26:2771-2782, Aug 2024. URL: https://doi.org/10.1007/s12094-024-03604-3, doi:10.1007/s12094-024-03604-3. This article has 19 citations and is from a peer-reviewed journal.
(schreiberhuber2024cervicalcancerscreening pages 1-2): Lena Schreiberhuber, James E. Barrett, Jiangrong Wang, Elisa Redl, Chiara Herzog, Charlotte D. Vavourakis, Karin Sundström, Joakim Dillner, and Martin Widschwendter. Cervical cancer screening using dna methylation triage in a real-world population. Nature Medicine, 30:2251-2257, Jun 2024. URL: https://doi.org/10.1038/s41591-024-03014-6, doi:10.1038/s41591-024-03014-6. This article has 85 citations and is from a highest quality peer-reviewed journal.
(schreiberhuber2024cervicalcancerscreening pages 2-3): Lena Schreiberhuber, James E. Barrett, Jiangrong Wang, Elisa Redl, Chiara Herzog, Charlotte D. Vavourakis, Karin Sundström, Joakim Dillner, and Martin Widschwendter. Cervical cancer screening using dna methylation triage in a real-world population. Nature Medicine, 30:2251-2257, Jun 2024. URL: https://doi.org/10.1038/s41591-024-03014-6, doi:10.1038/s41591-024-03014-6. This article has 85 citations and is from a highest quality peer-reviewed journal.
(schreiberhuber2024cervicalcancerscreening pages 4-5): Lena Schreiberhuber, James E. Barrett, Jiangrong Wang, Elisa Redl, Chiara Herzog, Charlotte D. Vavourakis, Karin Sundström, Joakim Dillner, and Martin Widschwendter. Cervical cancer screening using dna methylation triage in a real-world population. Nature Medicine, 30:2251-2257, Jun 2024. URL: https://doi.org/10.1038/s41591-024-03014-6, doi:10.1038/s41591-024-03014-6. This article has 85 citations and is from a highest quality peer-reviewed journal.
(schreiberhuber2024cervicalcancerscreening media 23da8e40): Lena Schreiberhuber, James E. Barrett, Jiangrong Wang, Elisa Redl, Chiara Herzog, Charlotte D. Vavourakis, Karin Sundström, Joakim Dillner, and Martin Widschwendter. Cervical cancer screening using dna methylation triage in a real-world population. Nature Medicine, 30:2251-2257, Jun 2024. URL: https://doi.org/10.1038/s41591-024-03014-6, doi:10.1038/s41591-024-03014-6. This article has 85 citations and is from a highest quality peer-reviewed journal.
(fischerova2024theroleof pages 1-2): Daniela Fischerova, Filip Frühauf, Andrea Burgetova, Ingfrid S. Haldorsen, Elena Gatti, and David Cibula. The role of imaging in cervical cancer staging: esgo/estro/esp guidelines (update 2023). Cancers, 16:775, Feb 2024. URL: https://doi.org/10.3390/cancers16040775, doi:10.3390/cancers16040775. This article has 50 citations.
(fischerova2024theroleof pages 26-27): Daniela Fischerova, Filip Frühauf, Andrea Burgetova, Ingfrid S. Haldorsen, Elena Gatti, and David Cibula. The role of imaging in cervical cancer staging: esgo/estro/esp guidelines (update 2023). Cancers, 16:775, Feb 2024. URL: https://doi.org/10.3390/cancers16040775, doi:10.3390/cancers16040775. This article has 50 citations.
(nagdev2026advancesinscreening pages 13-15): Priyanka Nagdev and Mythri Chittilla. Advances in screening, immunotherapy, targeted agents, and precision surgery in cervical cancer: a comprehensive clinical review (2018–2025). Current Oncology, Jan 2026. URL: https://doi.org/10.3390/curroncol33010048, doi:10.3390/curroncol33010048. This article has 1 citations.
(martinezcannon2024theevolvingrole pages 1-3): Bertha Alejandra Martinez-Cannon and Ilaria Colombo. The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer. Cancer Drug Resistance, Jun 2024. URL: https://doi.org/10.20517/cdr.2023.120, doi:10.20517/cdr.2023.120. This article has 18 citations.
(sznurkowski2024thepolishsociety pages 1-2): Jacek J. Sznurkowski, Lubomir Bodnar, Łukasz Szylberg, Agnieszka Zołciak-Siwinska, Anna Dańska-Bidzińska, Dagmara Klasa-Mazurkiewicz, Agnieszka Rychlik, Artur Kowalik, Joanna Streb, Mariusz Bidziński, and Włodzimierz Sawicki. The polish society of gynecological oncology guidelines for the diagnosis and treatment of cervical cancer (v2024.0). Journal of Clinical Medicine, 13:4351, Jul 2024. URL: https://doi.org/10.3390/jcm13154351, doi:10.3390/jcm13154351. This article has 10 citations.
(teixeira2024transitionfromopportunistic pages 1-2): Julio Cesar Teixeira, Diama Bhadra Vale, Cirbia Silva Campos, Ilana Polegatto, Joana Froes Bragança, Michelle Garcia Discacciati, and Luiz Carlos Zeferino. Transition from opportunistic cytological to organized screening program with dna-hpv testing detected prevalent cervical cancers 10 years in advance. Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-71735-2, doi:10.1038/s41598-024-71735-2. This article has 22 citations and is from a peer-reviewed journal.
(teixeira2024transitionfromopportunistic pages 2-4): Julio Cesar Teixeira, Diama Bhadra Vale, Cirbia Silva Campos, Ilana Polegatto, Joana Froes Bragança, Michelle Garcia Discacciati, and Luiz Carlos Zeferino. Transition from opportunistic cytological to organized screening program with dna-hpv testing detected prevalent cervical cancers 10 years in advance. Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-71735-2, doi:10.1038/s41598-024-71735-2. This article has 22 citations and is from a peer-reviewed journal.
(teixeira2024transitionfromopportunistic pages 5-5): Julio Cesar Teixeira, Diama Bhadra Vale, Cirbia Silva Campos, Ilana Polegatto, Joana Froes Bragança, Michelle Garcia Discacciati, and Luiz Carlos Zeferino. Transition from opportunistic cytological to organized screening program with dna-hpv testing detected prevalent cervical cancers 10 years in advance. Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-71735-2, doi:10.1038/s41598-024-71735-2. This article has 22 citations and is from a peer-reviewed journal.
(teixeira2024transitionfromopportunistic pages 5-6): Julio Cesar Teixeira, Diama Bhadra Vale, Cirbia Silva Campos, Ilana Polegatto, Joana Froes Bragança, Michelle Garcia Discacciati, and Luiz Carlos Zeferino. Transition from opportunistic cytological to organized screening program with dna-hpv testing detected prevalent cervical cancers 10 years in advance. Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-71735-2, doi:10.1038/s41598-024-71735-2. This article has 22 citations and is from a peer-reviewed journal.
(teixeira2024transitionfromopportunistic pages 4-5): Julio Cesar Teixeira, Diama Bhadra Vale, Cirbia Silva Campos, Ilana Polegatto, Joana Froes Bragança, Michelle Garcia Discacciati, and Luiz Carlos Zeferino. Transition from opportunistic cytological to organized screening program with dna-hpv testing detected prevalent cervical cancers 10 years in advance. Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-71735-2, doi:10.1038/s41598-024-71735-2. This article has 22 citations and is from a peer-reviewed journal.
(nagdev2026advancesinscreening pages 2-4): Priyanka Nagdev and Mythri Chittilla. Advances in screening, immunotherapy, targeted agents, and precision surgery in cervical cancer: a comprehensive clinical review (2018–2025). Current Oncology, Jan 2026. URL: https://doi.org/10.3390/curroncol33010048, doi:10.3390/curroncol33010048. This article has 1 citations.
(bray2024globalcancerstatistics pages 26-26): Freddie Bray, Mathieu Laversanne, Hyuna Sung, Jacques Ferlay, Rebecca L. Siegel, Isabelle Soerjomataram, and Ahmedin Jemal. Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74:229-263, Apr 2024. URL: https://doi.org/10.3322/caac.21834, doi:10.3322/caac.21834. This article has 35815 citations and is from a domain leading peer-reviewed journal.
(fischerova2024theroleof pages 7-8): Daniela Fischerova, Filip Frühauf, Andrea Burgetova, Ingfrid S. Haldorsen, Elena Gatti, and David Cibula. The role of imaging in cervical cancer staging: esgo/estro/esp guidelines (update 2023). Cancers, 16:775, Feb 2024. URL: https://doi.org/10.3390/cancers16040775, doi:10.3390/cancers16040775. This article has 50 citations.
(fischerova2024theroleof pages 6-7): Daniela Fischerova, Filip Frühauf, Andrea Burgetova, Ingfrid S. Haldorsen, Elena Gatti, and David Cibula. The role of imaging in cervical cancer staging: esgo/estro/esp guidelines (update 2023). Cancers, 16:775, Feb 2024. URL: https://doi.org/10.3390/cancers16040775, doi:10.3390/cancers16040775. This article has 50 citations.
(manso2024seomgeicoclinicalguidelines pages 4-5): Luis Manso, Avinash Ramchandani-Vaswani, Ignacio Romero, Luisa Sánchez-Lorenzo, María José Bermejo-Pérez, Purificación Estévez-García, Lorena Fariña-Madrid, Yolanda García García, Marta Gil-Martin, and María Quindós. Seom-geico clinical guidelines on cervical cancer (2023). Clinical & Translational Oncology, 26:2771-2782, Aug 2024. URL: https://doi.org/10.1007/s12094-024-03604-3, doi:10.1007/s12094-024-03604-3. This article has 19 citations and is from a peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Classifications

Subtypes

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Treatments

Biochemical Markers

Source YAML

References & Deep Research

References

Deep Research

1. Disease Information

1.1 Concise overview

1.2 Common synonyms / alternative names (not exhaustive)

1.3 Evidence provenance

2. Etiology

2.1 Primary causal factors

2.2 Risk factors and co-factors (evidence available in retrieved sources)

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes (clinical presentation)

4. Genetic / Molecular Information

4.1 Key molecular concepts (HPV-driven carcinogenesis)

4.2 Epigenetics and methylation biomarkers (2024 primary research)

5. Environmental Information

6. Mechanism / Pathophysiology

6.1 Causal chain (high-level)

6.2 Immune system involvement and implications

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

9.1 Epidemiology (recent authoritative statistics)

9.2 Sex ratio

10. Diagnostics

10.1 Screening tests and triage (recent advances)

10.2 Imaging and staging (ESGO/ESTRO/ESP update 2023; published 2024)

11. Outcome / Prognosis

11.1 Screening-associated stage shift (population implementation)

11.2 Advanced/recurrent metastatic disease outcomes (selected trial outcomes as summarized in authoritative reviews)

12. Treatment

12.1 Guideline-based treatment framework (2024 European/Spanish and national guidance)

12.2 Systemic therapy and immunotherapy integration

12.3 Targeted therapy / ADC

12.4 MAXO (Medical Action Ontology) suggestions (non-exhaustive; ontology IDs not retrieved)

13. Prevention

13.1 Primary prevention

13.2 Secondary prevention (screening)

13.3 Real-world implementation example (organized screening)

14. Other Species / Natural Disease

15. Model Organisms

Key 2023–2024 Developments Highlighted by the Retrieved Evidence

URLs and publication dates (where available in retrieved sources)